TNFRSF8 and anaplastic large cell lymphoma: This ADC presented very high potency against CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma cells in vitro, with IC50 of 3 to 50 pM, while non-expressing CD30 cells were ~1000 times more resistant [196].